| |
Wednesday, April 9, 2025 | 10am ET / 7am PT Learn the key steps for successfully entering Japan’s pharmaceutical market. This webinar covers regulatory requirements, compliance strategies, supply chain best practices, and common challenges. Gain expert insights to navigate this high-potential market with confidence. Don’t miss out—register now to secure your spot! 
|
|
Today’s Big NewsApr 2, 2025 |
|
Wednesday, April 9, 2025 | 11am ET / 8am PT Health systems around the globe face a difficult paradox: delivering more care with fewer resources. In this exclusive webinar, our expert panel will explore how AI-based solutions are addressing these challenges with real-world examples, experience, and published outcomes in ASCO and Nature. Register now. 
|
|
| By Angus Liu To innovators in the cell and gene therapy field, Peter Marks’ exit from the FDA means losing a seasoned regulator and key ally. |
|
|
|
By Gabrielle Masson The American Public Health Association and several researchers are suing the NIH and the HHS—plus respective leaders Jay Bhattacharya, M.D., Ph.D., and Robert F. Kennedy Jr.—in an effort to reverse and prevent further cancellations of federal research grants. |
By Kevin Dunleavy With its multiple sclerosis powerhouse Ocrevus expected to lose patent protection by the end of the decade and face competition from cheaper biosimilars, Roche is looking for ways to extend its exclusivity for the top-selling drug in the indication. But the Swiss company can check one potential solution off its list as a phase 3 trial of its high-dose version of Ocrevus in patients with relapsing multiple sclerosis (RMS) has failed to move the needle. |
By Eric Sagonowsky,Fraiser Kansteiner Amid a dramatic reshaping of the federal healthcare apparatus, the FDA has named an acting leader of its Center for Biologics Evaluation and Research. |
|
Thursday, April 10, 2025 | 11am ET / 8am PT Cell and gene therapies offer hope for previously untreatable diseases, with viral vectors currently favored as the primary gene delivery method. However, the complexities pose key challenges. In this webinar, learn how to choose the right production platform for achieving commercial timelines and managing manufacturing costs. Register now. 
|
|
By Gabrielle Masson The FDA’s Chief Medical Officer Hilary Marston, M.D., is leaving her position at the agency amid huge cuts to staff across the FDA. |
By Gabrielle Masson In the upcoming weeks, Tesla CEO Elon Musk is expected to step down from his position helming the federal Department of Government Efficiency (DOGE), according to Politico. |
By Andrea Park As the college basketball March Madness tournament gets underway, so too does Fierce Pharma Marketing’s annual #FierceMadness competition. |
By Kevin Dunleavy Boehringer Ingelheim picked a challenging day to reveal its 2024 financial results and guidance for this year. With President Donald Trump announcing his plan on tariffs on Wednesday and uncertainty surrounding if and how they will affect the export of pharmaceutical products to the U.S., the German company is treading lightly with its projection of a “slight year-on-year increase” in revenue. |
By Darren Incorvaia The Trump administration is halting research funding to Princeton University and reviewing more than $9 billion in federal grants and contracts to Harvard University, the latest escalation of the government’s cuts to scientific research institutions. |
By Darren Incorvaia British biotech CellCentric is settling into a new office in Boston, part of the company’s expansion into the U.S. as multiple myeloma asset inobrodib progresses to late-stage clinical development. |
By Conor Hale Following the FDA clearance of its Versius robot last fall, CMR Surgical has raised more than $200 million in new funding to bolster its U.S. commercial launch. |
By Conor Hale The medtech giant plans to integrate Methinks AI’s apps with its portfolio of ischemic stroke treatment hardware, including blood clot aspiration systems and stent-based retrievers. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we hear from Nada Hanafi, co-founder of MedTech Color, about the importance of diversity in healthcare settings. |
|
|---|
|
|
|
Antibody-drug conjugates (ADCs) and radioisotope therapies (RITs) offer targeted therapies that effectively attack tumor cells while minimizing harm to surrounding healthy tissue. However, the right design of ADC and RIT trials is critical. Access this report to learn about the pivotal role of advanced medical imaging. Download here. 
|
|
Research We interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Read about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
Whitepaper Develop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| Accepting Nominations Now |
|
| Accepting Nominations Now |
|
|
| |
|
